Scarica l'app Stockscreener
6.74
0.74%
-0.05
Dopo l'orario di chiusura:
6.67
-0.07
-1.04%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CAPR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$6.79
Aprire:
$7.03
Volume 24 ore:
1.97M
Relative Volume:
0.68
Capitalizzazione di mercato:
$307.86M
Reddito:
$27.10M
Utile/perdita netta:
$-24.31M
Rapporto P/E:
-8.1205
EPS:
-0.83
Flusso di cassa netto:
$-33.33M
1 W Prestazione:
+3.37%
1M Prestazione:
-39.55%
6M Prestazione:
-52.77%
1 anno Prestazione:
+58.59%
Intervallo 1D:
$6.61
$7.10
Intervallo di 1 settimana:
$6.26
$7.28
Portata 52W:
$3.52
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Nome
Capricor Therapeutics Inc
Settore
Industria
Telefono
(310) 358-3200
Indirizzo
8840 WILSHIRE BLVD, BEVERLY HILLS, CA
Confronta CAPR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
6.74 | 310.36M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 118.34B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.14 | 60.31B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.55 | 42.35B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
598.79 | 36.43B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
305.74 | 31.87B | 3.81B | -644.79M | -669.77M | -6.24 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-30 | Iniziato | Alliance Global Partners | Buy |
| 2025-06-26 | Iniziato | B. Riley Securities | Buy |
| 2025-05-20 | Iniziato | Roth Capital | Buy |
| 2024-10-21 | Iniziato | Piper Sandler | Overweight |
| 2024-05-17 | Iniziato | Oppenheimer | Outperform |
| 2024-01-05 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-10-26 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-12-26 | Downgrade | Maxim Group | Buy → Hold |
| 2018-01-26 | Reiterato | H.C. Wainwright | Buy |
| 2017-09-15 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-13 | Ripresa | Rodman & Renshaw | Buy |
| 2016-07-06 | Ripresa | H.C. Wainwright | Buy |
| 2016-06-15 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Capricor Therapeutics Inc Borsa (CAPR) Ultime notizie
Shareholders that lost money on Capricor Therapeutics should contact Faruqi & Faruqi about pending Class ActionCAPR - The Malaysian Reserve
Capricor Investors Sue Over Misleading FDA Approval Claims – What You Need to Know - TradingView
Capricor Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before September 15, 2025 to Discuss Your RightsCAPR - PR Newswire
Shareholders of Capricor Therapeutics, Inc. (CAPR): Protect Your Rights Before September 15, 2025Contact Levi & Korsinsky - TradingView
What makes Capricor Therapeutics Inc. stock price move sharplyAI Triggered Buy Zone Forecast System - Newser
How to manage a losing position in Capricor Therapeutics Inc.Daily Profit Watch With Forecast Confidence - Newser
Class Action Filed Against Capricor Therapeutics, Inc. - GlobeNewswire
Bragar Eagel & Squire, P.C. Urges Investors in XPLR - GlobeNewswire
Bragar Eagel & Squire, P.C. Urges Investors in XPLR Infrastructure, Centene, Biohaven, or Capricor to Inquire About Their Rights in Class Action Lawsuits - GlobeNewswire Inc.
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc.CAPR - FinancialContent
Capricor Therapeutics to Host Webinar on Deramiocel and Duchenne Muscular Dystrophy in Collaboration with Parent Project Muscular Dystrophy - Quiver Quantitative
Capricor Therapeutics and Parent Project Muscular Dystrophy - GlobeNewswire
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments in the Deramiocel Program for the Treatment of Duchenne Muscular Dystrophy - Yahoo Finance
Class Action Filed Against Capricor Therapeutics, Inc. (CAPR) Seeking Recovery for InvestorsContact The Gross Law Firm - PR Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Relative strength of Capricor Therapeutics Inc. in sector analysisAI Entry Timing Prediction for Swing Traders - Newser
What is the risk reward ratio of investing in Capricor Therapeutics Inc. stockTrack emerging stocks with high growth potential - jammulinksnews.com
Lost Money on Capricor Therapeutics, Inc. (CAPR)? Contact Levi & Korsinsky Before September 15, 2025 to Join Class Action - ACCESS Newswire
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ACCESS Newswire
What are analysts’ price targets for Capricor Therapeutics Inc. in the next 12 monthsBuild your wealth with consistent stock growth - jammulinksnews.com
Investors who lost money on Capricor Therapeutics, Inc. - GlobeNewswire
CAPR Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the ... - Bluefield Daily Telegraph
CAPR Class Action Alert: Robbins LLP Reminds Investors of - GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP - GlobeNewswire
Join Class Action to Recover Losses from Capricor Therapeutics, Inc. (CAPR)Contact Levi & Korsinsky Before September 15, 2025 - Newsfile
Levi & Korsinsky Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025CAPR - PR Newswire
Should I buy Capricor Therapeutics Inc. stock before earningsHigh-yield capital appreciation - jammulinksnews.com
What analysts say about Capricor Therapeutics Inc. stockUnstoppable trading performance - Autocar Professional
Is Capricor Therapeutics Inc. a good long term investmentSignificant capital appreciation - Autocar Professional
Investors who lost money on Capricor Therapeutics, - GlobeNewswire
Capricor Therapeutics Inc. Stock Analysis and ForecastExtraordinary earning power - PrintWeekIndia
Arizona State Retirement System Buys Shares of 11,707 Capricor Therapeutics, Inc. (NASDAQ:CAPR) - Defense World
Shareholders that lost money on Capricor Therapeutics, Inc.(CAPR) Urged to Join Class ActionContact The Gross Law Firm to Learn More - Barchart.com
Recover Investment Losses: Levi & Korsinsky Files Class Action Against Capricor Therapeutics, Inc. (CAPR) - TradingView
CAPRICOR THERAPEUTICS, INC. (NASDAQ:CAPR) DEADLINE ALERT Bernstein Liebhard LLP Reminds Capricor Therapeutics, Inc. Investors of Upcoming Deadline - ACCESS Newswire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics - ETX View
What drives Capricor Therapeutics Inc. stock priceOutperformance with explosive growth - jammulinksnews.com
Capricor Therapeutics, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsCAPR - Business Wire
Levi & Korsinsky Announces the Filing of a Securities Class - GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Capricor - GlobeNewswire
Capricor Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025CAPR - PR Newswire
Behind Capricor Therapeutics Inc’s 52-Week Range: Uncovering Opportunities for Investors - investchronicle.com
Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 15% loss last week hit both individual investors who own 47% as well as institutions - simplywall.st
Capricor Therapeutics, Inc. Securities Fraud Class Action - GlobeNewswire
CAPRICOR THERAPEUTICS, INC. (NASDAQ: CAPR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Capricor Therapeutics, Inc. Investors of Upcoming Deadline - ACCESS Newswire
(CAPR) Technical Data - news.stocktradersdaily.com
Securities Fraud and Market Volatility in Biotech: Lessons from Capricor's Downfall - AInvest
Rosen Law Firm Urges Capricor Therapeutics, Inc. (NASDAQ: CAPR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - Business Wire
Investors Urged to Contact Levi & Korsinsky for Information Before September 15, 2025Capricor Therapeutics, Inc. (CAPR) - TradingView
Capricor Therapeutics Inc Azioni (CAPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
10.28%
2.59%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):